To further enhance the quality of Pharmacoepidemiology (ISSN: 2813-0618) and the papers published in it, under the guidance of our Editor-in-Chief, Dr. Carlotta Franchi, the journal has updated and revised its aims and scope. The original scope and the updated version are listed below.
|
Scope (new version):
|
Scope (old version):
|
|
Pharmacoepidemiology welcomes manuscripts covering a broad range of areas including, but not limited to, the following:
- Designs, analyses, results, and interpretations of studies on drugs, biologics, or medical devices;
- Molecular pharmacoepidemiology;
- The methodology of pharmacoepidemiology;
- Pharmacovigilance/preventative pharmacovigilance/ecopharmacovigilance;
- Patient safety;
- Pharmacoepidemiology studies in targeted populations and settings;
- Patterns of drug utilization;
- Patterns of drug prescription, appropriateness of prescriptions, overprescription;
- Polypharmacology;
- Randomized control trials on drugs;
- Systematic review or meta-analysis related to drugs;
- Post-marketing surveillance;
- Pharmacoeconomics;
- The formulation and interpretation of regulatory guidelines;
- Studies on the benefits/safety/effectiveness of pharmaceuticals, biologics, or medical devices;
- Harm/benefit assessments in drug therapy;
- The evaluation of risk management plans on pharmaceuticals, biologics, and medical devices.
|
Pharmacoepidemiology welcomes manuscripts covering a broad range of areas including, but not limited to:
- designs, analyses, results, and interpretations of studies on drugs, biologics, or medical devices;
- molecular pharmacoepidemiology;
- the methodology of pharmacoepidemiology;
- pharmacovigilance;
- patient safety;
- patterns of drug utilization;
- post-marketing surveillance;
- pharmacoeconomics;
- the formulation and interpretation of regulatory guidelines;
- studies on the benefits/safety/effectiveness of pharmaceuticals, biologics, or medical devices;
- harm/benefit assessments in drug therapy;
- the evaluation of risk management plans on pharmaceuticals, biologics and medical devices.
|
For more detailed information, please visit the following link: https://www.mdpi.com/journal/pharmacoepidemiology/about.
Pharmacoepidemiology Editorial Office